PT  - JOURNAL ARTICLE
AU  - Jahn, Katharina
AU  - Dreifuss, David
AU  - Topolsky, Ivan
AU  - Kull, Anina
AU  - Ganesanandamoorthy, Pravin
AU  - Fernandez-Cassi, Xavier
AU  - Bänziger, Carola
AU  - Stachler, Elyse
AU  - Fuhrmann, Lara
AU  - Jablonski, Kim Philipp
AU  - Chen, Chaoran
AU  - Aquino, Catharine
AU  - Stadler, Tanja
AU  - Ort, Christoph
AU  - Kohn, Tamar
AU  - Julian, Timothy R.
AU  - Beerenwinkel, Niko
TI  - Detection of SARS-CoV-2 variants in Switzerland by genomic analysis of wastewater samples
AID  - 10.1101/2021.01.08.21249379
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.08.21249379
4099  - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249379.short
4100  - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249379.full
AB  - The SARS-CoV-2 lineages B.1.1.7 and 501.V2, which were first detected in the United Kingdom and South Africa, respectively, are spreading rapidly in the human population. Thus, there is an increased need for genomic and epidemiological surveillance in order to detect the strains and estimate their abundances. Here, we report a genomic analysis of SARS-CoV-2 in 48 raw wastewater samples collected from three wastewater treatment plants in Switzerland between July 9 and December 21, 2020. We find evidence for the presence of several mutations that define the B.1.1.7 and 501.V2 lineages in some of the samples, including co-occurrences of up to three B.1.1.7 signature mutations on the same amplicon in four samples from Lausanne and one sample from a Swiss ski resort dated December 9 - 21. These findings suggest that the B.1.1.7 strain could be detected by mid December, two weeks before its first verification in a patient sample from Switzerland. We conclude that sequencing SARS-CoV-2 in community wastewater samples may help detect and monitor the circulation of diverse lineages.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the SIB Swiss Institute of Bioinformatics as a Competitive Resource, the Swiss National Science Foundation (project 31CA30 196538), Eawag discretionary funds and an EPFL COVID19 grant. XFC was a fellow of the EU Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 754462. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approvals were necessary for this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon publication.Requests can be forwarded to Maurizio Bartolucci maurizio.bartolucci{at}uslcentro.toscana.it or Matteo Benelli matteo.benelli{at}uslcentro.toscana.it https://github.com/cgplab/covidapp